The emerging role of the gut microbiota and its application in inflammatory bowel disease
Year: 2024
Type: review
Abstract: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a complex disorder with an unknown cause. However, the dysbiosis of the gut microbiome has been found to play a role in IBD etiology, including exacerbated immune responses and defective intestinal barrier integrity. The gut microbiome can also be a potential biomarker for several diseases, including IBD. Currently, conventional treatments targeting pro-inflammatory cytokines and pathways in IBD-associated dysbiosis do not yield effective results. Other therapies that directly target the dysbiotic microbiome for effective outcomes are emerging. We review the role of the gut microbiome in health and IBD and its potential as a diagnostic, prognostic, and therapeutic target for IBD. This review also explores emerging therapeutic advancements that target gut microbiome-associated alterations in IBD, such as nanoparticle or encapsulation delivery, fecal microbiota transplantation, nutritional therapies, microbiome/probiotic engineering, phage therapy, mesenchymal stem cells (MSCs), gut proteins, and herbal formulas.
Source: Biomedicine & Pharmacotherapy
Authors: Xiu Wang, Jianhua Peng, Peipei Cai, Yuxuan Xia, Chengxue Yi, Anquan Shang, Francis Atim Akanyibah, Fei Mao
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gut microbiota, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dysbiosis, intestinal barrier integrity, immune response, biomarkers, fecal microbiota transplantation, probiotics, phage therapy, mesenchymal stem cells, nanoparticle delivery, nutritional therapy, herbal formula, microbiome engineering
Open Access status: gold
Estimated APC paid: $3,420
Funder: Government of Jiangsu Province
Award: G7031880050
OpenAlex ID: W4401698446
